Cargando…
Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence
Uterine myoma is the most common benign uterine tumor in women of reproductive age and occurs in 20%–25% of the worldwide population. No currently approved medical treatment is able to completely eliminate fibroids. Surgery, particularly hysterectomy, predominates as the treatment strategy of choice...
Autores principales: | Trefoux Bourdet, Alice, Luton, Dominique, Koskas, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381886/ https://www.ncbi.nlm.nih.gov/pubmed/25848323 http://dx.doi.org/10.2147/IJWH.S50016 |
Ejemplares similares
-
Ulipristal acetate as a treatment option for uterine fibroids
por: Piecak, Karolina, et al.
Publicado: (2017) -
Successful Pregnancy after Treatment with Ulipristal Acetate for Uterine Fibroids
por: Monleón, Javier, et al.
Publicado: (2014) -
Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids
por: Middelkoop, Mei-An, et al.
Publicado: (2022) -
Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids
por: Biglia, Nicoletta, et al.
Publicado: (2014) -
Safety after extended repeated use of ulipristal acetate for uterine fibroids
por: Fauser, Bart C. J. M., et al.
Publicado: (2017)